GO:0032008 positive regulation of TOR signaling: Nutrient-Sensing Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032008 (positive regulation of TOR signaling) describes any process that activates or increases the frequency, rate or extent of TOR signaling, the central nutrient-sensing pathway controlling cell growth.
• The mechanistic target of rapamycin (mTOR) nucleates two complexes, mTORC1 and mTORC2; mTORC1 is the canonical TOR signaling output regulated by nutrients, growth factors and stress.
• Amino acid sensors such as Sestrin2 transmit leucine availability to mTORC1, providing a direct molecular entry point for positive regulation of TOR signaling.
• Positive regulation of TOR signaling is hijacked in cancer, where oncogenic drivers such as FOXM1-ZIC2-UBE2C and metabolic enzymes such as IMPDH2 and FABP5 converge on AKT/mTOR to sustain proliferation [4,5,6].
• TOR signaling strength shapes immune cell fate, controlling CD8+ T memory versus exhaustion programs and CD4+ T cell activation [6,8].
• Clinically, positive regulation of TOR signaling is druggable: everolimus, an mTOR inhibitor, is approved for several malignancies, validating the pathway as a therapeutic target.
Description
Positive regulation of TOR signaling (GO:0032008) is the biological process that activates or increases the frequency, rate or extent of TOR signaling, the evolutionarily conserved pathway through which cells couple nutrient and growth-factor availability to biomass accumulation. The term sits at the top of a signaling hierarchy that determines whether a cell grows, divides, autophagically recycles or becomes quiescent, making it one of the most intensively studied nodes in cell biology. Because the pathway integrates inputs from amino acids, glucose, lipids and immune receptors, its positive regulation is both a homeostatic necessity and a common driver of disease [1,6]. At the molecular core, TOR kinase exists in two multiprotein complexes, TORC1 and TORC2; TORC1 is the principal nutrient-sensitive arm and the main target of positive regulatory inputs. Upstream activators include amino acid sensors such as Sestrin2, which binds leucine and relays its availability to the complex, as well as growth-factor cascades that impinge on AKT and mTOR [1,6]. Downstream, TORC1 phosphorylates effectors that promote translation, lipogenesis and nucleotide synthesis while suppressing autophagy, thereby converting a positive regulatory signal into a coherent anabolic program. For researchers, GO:0032008 provides a standardized annotation axis for interrogating how specific genes, mutations and environmental cues shift TOR signaling output. Dysregulated positive regulation is observed in solid tumors and hematologic malignancies, in neurodegenerative microglial states, and in autoimmune T cell activation, underscoring its translational relevance [2,3,4,5,6]. This article synthesizes the QuickGO definition with verified primary literature to outline the mechanism, key genes, disease links and experimental strategies for studying positive regulation of TOR signaling.
positive regulation of TOR signaling At A Glance
| GO ID | GO:0032008 |
|---|---|
| GO term | positive regulation of TOR signaling |
| Ontology | biological_process |
| Synonym | activation of TOR signaling pathway; positive regulation of target of rapamycin signaling pathway; positive regulation of TOR signaling cascade; upregulation of TOR signaling pathway |
| Major function | Activates or increases the frequency, rate or extent of TOR signaling, promoting anabolic cell growth |
| Key upstream sensors | Sestrin2 (leucine sensor), AKT/mTOR axis, immune receptor signaling [1,6] |
| Key downstream outputs | Protein synthesis, lipogenesis, nucleotide synthesis, autophagy suppression |
| Disease relevance | Cancer, Parkinson's disease microglial dysfunction, myasthenia gravis, T cell exhaustion [2,4,5,6,8] |
| Therapeutic angle | mTOR inhibitors such as everolimus block positive TOR signaling in tumors |
What Is GO:0032008?
In plain terms, GO:0032008 describes every cellular event that switches TOR signaling on or makes it stronger. Formally, it is any process that activates or increases the frequency, rate or extent of TOR signaling, where TOR signaling is the signal transduction cascade initiated by the target of rapamycin kinase. The term is a biological process annotation and is agnostic to the specific upstream molecule: it covers nutrient sensing by Sestrin2, growth-factor-driven AKT activation, and any genetic or pharmacological manipulation that elevates TOR pathway activity [1,6].
Why Is positive regulation of TOR signaling Important in Cell Biology?
Positive regulation of TOR signaling is important because it is the decisive switch that determines whether a cell invests in growth or conserves resources, and because its dysregulation is a recurring theme in cancer, immune disorders and neurodegeneration [2,3,4,5,6]. Understanding which genes positively regulate TOR signaling, and how mutations alter that regulation, is therefore central to both basic cell biology and therapeutic development [1,7].
• Controls cell growth and proliferation by gating translation, lipogenesis and nucleotide synthesis.
• Integrates amino acid availability through sensors such as Sestrin2, linking diet to signaling.
• Drives oncogenesis when hyperactivated by oncogenes such as FOXM1-ZIC2-UBE2C.
• Supports metabolic reprogramming in colorectal cancer via FABP5-mTOR crosstalk.
• Shapes T cell fate decisions, including CD8+ memory versus exhaustion.
• Contributes to autoimmune activation of CD4+ T cells in myasthenia gravis.
• Modulates microglial function and alpha-synuclein pathology in Parkinson's disease.
• Provides a validated drug target, exemplified by the approved mTOR inhibitor everolimus.
• Serves as a biomarker axis for pathway-addiction stratification in tumors [3,5].
• Offers a tractable experimental system for CRISPR screens and functional genomics.
What Happens During positive regulation of TOR signaling?
Nutrient sensing and signal initiation
In simple terms: The cell first checks whether amino acids such as leucine are available, and if so, it sends a go signal to TOR.
Positive regulation of TOR signaling begins with nutrient sensing. Sestrin2 acts as a leucine sensor that binds leucine and thereby relays amino acid availability to the mTORC1 pathway, enabling the complex to respond to nutrient status. This sensing step converts a metabolic input into a biochemical activation signal, positioning Sestrin2 as an upstream positive regulator of TOR signaling. Growth factors and immune receptor inputs can also initiate the cascade through AKT-dependent mechanisms.
Assembly and activation of TORC1
In simple terms: The TOR kinase partners with raptor to form a nutrient-sensitive machine that can signal to the growth machinery.
The core activation event is the formation of the nutrient-sensitive TORC1 complex. mTOR interacts with raptor to form a complex that signals to the cell growth machinery, and this interaction is nutrient-sensitive. Positive regulation of TOR signaling therefore requires proper assembly and activation of this complex, which then phosphorylates downstream substrates to promote anabolic processes.
Downstream anabolic output
In simple terms: Once switched on, TOR tells the cell to build proteins, fats and nucleotides while pausing recycling.
Activated TOR signaling drives a coordinated anabolic program. The pathway signals to the cell growth machinery, promoting protein synthesis and biomass accumulation while suppressing catabolic processes such as autophagy. In cancer contexts, this output is amplified by oncogenic circuits; for example, FOXM1-regulated ZIC2 promotes malignant phenotypes by activating UBE2C/mTOR signaling. Similarly, FABP5 suppresses colorectal cancer progression via mTOR-mediated autophagy by decreasing FASN expression, illustrating how downstream metabolic enzymes feed back into TOR output.
Integration with immune and metabolic signals
In simple terms: TOR signaling also listens to the immune system and to metabolic enzymes, so activation can come from many directions.
Positive regulation of TOR signaling is not restricted to nutrients. IMPDH2 facilitates CD4+ T cell activation through the AKT/mTOR pathway by upregulating SRPK1 in myasthenia gravis, showing that metabolic enzymes can positively regulate TOR signaling in autoimmune settings. In the brain, TREM2 signaling regulates microglial function and alpha-synuclein pathology, linking immune receptor signaling to TOR-associated microglial states in Parkinson's disease. These examples demonstrate that positive regulation of TOR signaling is a convergence point for diverse physiological inputs [2,6].
Feedback and pathway tuning
In simple terms: The pathway has brakes and feedback loops so that activation is transient and proportional to need.
Because sustained TOR activation is deleterious, positive regulation is balanced by feedback mechanisms. The pathway's output influences T cell memory and exhaustion programs, indicating that the duration and strength of TOR signaling are actively tuned during immune responses. Pharmacological blockade with everolimus demonstrates that the pathway can be dampened, confirming that positive regulation is a reversible, targetable process.
Key Genes Involved in GO:0032008 positive regulation of TOR signaling
The following genes and proteins are experimentally implicated in positive regulation of TOR signaling or its downstream outputs, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MTOR | Core kinase of TORC1 and TORC2; interacts with raptor to form nutrient-sensitive complex | Central node for knockout and point-mutation studies of pathway activation |
| RPTOR (raptor) | Scaffold that partners with mTOR to form nutrient-sensitive TORC1 | Target for dissecting complex assembly and nutrient sensing |
| SESN2 (Sestrin2) | Leucine sensor that relays amino acid availability to mTORC1 | Key upstream positive regulator; model for nutrient-sensing studies |
| AKT1 | Growth-factor kinase upstream of mTOR; mediates IMPDH2-driven T cell activation | Target for phospho-signaling and inhibitor studies |
| IMPDH2 | Metabolic enzyme that facilitates CD4+ T cell activation via AKT/mTOR by upregulating SRPK1 | Autoimmune disease model target |
| SRPK1 | Upregulated by IMPDH2; supports AKT/mTOR pathway activation | Candidate modifier of TOR signaling in autoimmunity |
| FOXM1 | Transcription factor regulating ZIC2, which activates UBE2C/mTOR signaling | Oncogenic upstream regulator in renal clear cell carcinoma |
| ZIC2 | FOXM1-regulated factor promoting malignant phenotype via UBE2C/mTOR | Target for cancer pathway activation studies |
| UBE2C | Ubiquitin-conjugating enzyme in the UBE2C/mTOR axis | Potential node linking ubiquitination to TOR activation |
| FABP5 | Suppresses colorectal cancer progression via mTOR-mediated autophagy by decreasing FASN | Context-dependent regulator of mTOR output |
| FASN | Fatty acid synthase whose decrease by FABP5 modulates mTOR-mediated autophagy | Metabolic crosstalk target |
| TREM2 | Immune receptor regulating microglial function and alpha-synuclein pathology | Neurodegeneration model for TOR-associated microglial states |
| CD8+ T cells (context) | TOR signaling regulates memory and exhaustion programs | Immunology model for pathway strength and duration |
| CD4+ T cells (context) | Activated through AKT/mTOR by IMPDH2-SRPK1 in myasthenia gravis | Autoimmune model for positive TOR regulation |
How Is positive regulation of TOR signaling Regulated?
Positive regulation of TOR signaling is itself tightly regulated. Upstream, Sestrin2 senses leucine and transmits nutrient availability to mTORC1, so leucine abundance positively regulates the pathway. Growth-factor and immune inputs converge on AKT, which can be engaged by IMPDH2-SRPK1 signaling during CD4+ T cell activation. Downstream, the pathway controls autophagy and biosynthetic programs, and its strength determines T cell memory versus exhaustion outcomes. Pharmacological inhibition by everolimus shows that the pathway can be negatively regulated, providing a benchmark for the reversibility of positive regulation.
positive regulation of TOR signaling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ZIC2 / UBE2C / FOXM1 | Renal clear cell carcinoma malignant phenotype | Knockout of ZIC2 in renal carcinoma cell lines; mTOR phospho-readout |
| FABP5 / FASN | Colorectal cancer progression and autophagy | Overexpression and knockout of FABP5 in colorectal cancer cells |
| IMPDH2 / SRPK1 | Myasthenia gravis CD4+ T cell activation | Knockdown of IMPDH2 in primary CD4+ T cells; AKT/mTOR immunoblot |
| TREM2 | Parkinson's disease microglial function and alpha-synuclein pathology | TREM2 knockout microglia; alpha-synuclein seeding assays |
| MTOR / RPTOR | General TOR signaling and growth control | CRISPR knockout of MTOR or RPTOR; nutrient-sensing assays |
Cancer
Positive regulation of TOR signaling is a hallmark of many cancers. In renal clear cell carcinoma, FOXM1-regulated ZIC2 promotes the malignant phenotype by activating UBE2C/mTOR signaling, directly linking an oncogenic transcriptional circuit to increased TOR pathway activity. In colorectal cancer, FABP5 suppresses progression via mTOR-mediated autophagy by decreasing FASN expression, illustrating that the direction of TOR-related effects can be context-dependent. The clinical approval of the mTOR inhibitor everolimus for cancer treatment confirms that blocking positive TOR signaling has therapeutic value.
Neurodegeneration and microglial biology
In Parkinson's disease, TREM2 signaling regulates microglial function and alpha-synuclein pathology, connecting immune receptor signaling to TOR-associated microglial states. This suggests that positive regulation of TOR signaling in microglia may influence neuroinflammatory responses and proteinopathy progression, making it a candidate axis for neurodegeneration research.
Autoimmunity and T cell activation
IMPDH2 facilitates CD4+ T cell activation through the AKT/mTOR pathway by upregulating SRPK1 in myasthenia gravis, providing a direct example of a metabolic enzyme positively regulating TOR signaling in an autoimmune disease. In parallel, TOR signaling regulates CD8+ T memory and exhaustion, so its positive regulation shapes the balance between protective immunity and immune dysfunction.
From positive regulation of TOR signaling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for TORC1 assembly? | CRISPR knockout of MTOR or RPTOR followed by co-immunoprecipitation |
| Does a point mutation alter nutrient sensing? | Point-mutation knock-in in SESN2 or MTOR with leucine-stimulation assays |
| Can a reporter track pathway activation in live cells? | Tagged knock-in of an mTOR substrate or fluorescent TOR-signaling reporter |
| Does overexpression of an oncogene increase TOR output? | Overexpression of ZIC2 or UBE2C with phospho-mTOR readouts |
| Does a metabolic enzyme modulate TOR in immune cells? | Knockout or overexpression of IMPDH2 in CD4+ T cells |
| Does a microglial receptor alter TOR-associated states? | TREM2 knockout or knock-in microglia with alpha-synuclein challenge |
How to Study the positive regulation of TOR signaling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-immunoblotting | Activation status of mTOR and its substrates | Confirming positive regulation after gene perturbation |
| Co-immunoprecipitation | Assembly of mTOR-raptor complexes | Testing nutrient-sensitive complex formation |
| CRISPR knockout | Requirement of a gene for pathway activity | Deleting MTOR, RPTOR or candidate regulators |
| CRISPR point mutation | Effect of specific residues on sensing | Dissecting Sestrin2 leucine sensing |
| Overexpression | Sufficiency of a gene to activate TOR | Testing ZIC2 or UBE2C oncogenic drive |
| RNA sequencing | Transcriptional output of TOR activation | Profiling anabolic and immune programs |
| Autophagy flux assay | Catabolic suppression by TOR | Studying FABP5-mTOR crosstalk in cancer |
| T cell activation assays | Immune functional consequence | Evaluating IMPDH2-SRPK1-AKT/mTOR in myasthenia gravis |
Phospho-signaling and immunoblotting
Because positive regulation of TOR signaling is defined by increased pathway activity, phospho-specific antibodies against mTOR substrates are standard readouts. Studies of the mTOR-raptor complex used biochemical analysis to show nutrient-sensitive signaling to the growth machinery. Similar approaches detect AKT/mTOR activation downstream of IMPDH2-SRPK1 in T cells.
Genetic perturbation with CRISPR
CRISPR knockout and knock-in enable causal testing of candidate positive regulators. Deleting MTOR or RPTOR ablates the core complex, while point mutations in nutrient sensors such as SESN2 can dissect sensing residues [1,7]. Overexpression of oncogenes like ZIC2 tests whether a candidate drives pathway activation.
Transcriptomic and proteomic profiling
RNA sequencing and proteomics reveal the downstream anabolic program triggered by positive TOR regulation, including translation and autophagy genes. In immune settings, profiling CD8+ T cells has linked TOR signaling strength to memory and exhaustion transcriptional states.
Functional assays for autophagy and growth
Autophagy flux assays and proliferation measurements capture the physiological consequences of TOR activation. FABP5-mTOR-mediated autophagy in colorectal cancer was assessed with autophagy markers, demonstrating how pathway output can be quantified. Growth assays complement phospho-signaling data to confirm functional positive regulation.
How CRISPR Can Be Used to Study GO:0032008 positive regulation of TOR signaling
Knockout
CRISPR knockout of MTOR or RPTOR eliminates the core TORC1 complex and provides a clean negative control for positive regulation studies. Knockout of upstream regulators such as SESN2 or IMPDH2 tests whether a candidate is required for pathway activation in nutrient or immune contexts [1,6].
Point Mutation
Point-mutation knock-in allows precise interrogation of sensing and catalytic residues. For example, mutating leucine-binding residues in Sestrin2 can determine whether nutrient sensing is preserved, directly probing positive regulation of TOR signaling. Similar strategies can target mTOR domains to separate complex assembly from kinase activity.
Knock-in
Tagged knock-in of mTOR pathway components enables live-cell imaging and endogenous-level expression studies. Knock-in reporters of TOR substrates allow quantitative tracking of pathway activation without overexpression artifacts. This is valuable for studying dynamic positive regulation in immune cells.
Overexpression
Overexpression of candidate oncogenes such as ZIC2 or UBE2C tests sufficiency for activating mTOR signaling in cancer models. Overexpression of FABP5 or IMPDH2 can reveal context-dependent effects on mTOR-mediated autophagy or T cell activation [4,6].
How EDITGENE Supports positive regulation of TOR signaling Research
Researchers studying positive regulation of TOR signaling-related genes often need to determine whether a candidate gene is causally involved in pathway activation or is merely correlated with it. CRISPR-based models provide the cleanest route from correlation to causation, and EDITGENE offers an integrated platform for generating and characterizing such models.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of TOR signaling research.
Frequently Asked Questions About positive regulation of TOR signaling
What is positive regulation of TOR signaling (GO:0032008)?
It is any biological process that activates or increases the frequency, rate or extent of TOR signaling, the nutrient-sensitive pathway controlling cell growth.
What genes are involved in positive regulation of TOR signaling?
Key genes include MTOR and RPTOR, which form the nutrient-sensitive TORC1 complex, and upstream regulators such as SESN2, AKT1, IMPDH2, SRPK1, FOXM1, ZIC2, UBE2C, FABP5 and FASN [1,4,5,6,7].
How does Sestrin2 regulate TOR signaling?
Sestrin2 acts as a leucine sensor that relays amino acid availability to the mTORC1 pathway, thereby positively regulating TOR signaling.
Why is positive regulation of TOR signaling important in cancer?
Hyperactivation of TOR signaling drives malignant phenotypes; for example, FOXM1-regulated ZIC2 promotes renal clear cell carcinoma via UBE2C/mTOR, and mTOR inhibitors such as everolimus are used clinically [3,5].
Is TOR signaling involved in immune cell function?
Yes. TOR signaling regulates CD8+ T memory and exhaustion, and IMPDH2 facilitates CD4+ T cell activation through AKT/mTOR in myasthenia gravis [6,8].
What diseases are linked to TOR signaling dysregulation?
Cancer, Parkinson's disease microglial dysfunction, myasthenia gravis and immune exhaustion states have been linked to altered TOR signaling [2,3,4,5,6,8].
How do researchers study positive regulation of TOR signaling?
Common methods include phospho-immunoblotting, co-immunoprecipitation, CRISPR knockout or point mutation, overexpression, RNA sequencing and autophagy flux assays [1,4,6,7,8].
What is the role of mTORC1 in TOR signaling?
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery, making mTORC1 the principal output of positive TOR regulation.
Can CRISPR be used to study TOR signaling?
Yes. CRISPR knockout, point mutation, knock-in and overexpression models allow causal testing of candidate regulators of TOR signaling [1,5,6,7].
What drugs target positive regulation of TOR signaling?
Everolimus is an approved mTOR inhibitor that blocks TOR signaling and is used in cancer therapy, validating the pathway as a drug target.
Conclusion
Positive regulation of TOR signaling (GO:0032008) is a central biological process that converts nutrient, growth-factor and immune inputs into an anabolic growth program through the mTORC1 complex and its upstream sensors such as Sestrin2 [1,7]. Its dysregulation contributes to cancer, neurodegeneration and autoimmune T cell activation, and it is validated as a therapeutic target by the approved inhibitor everolimus [2,3,4,5,6]. Continued work using CRISPR knockout, point-mutation, knock-in and overexpression models will clarify which genes causally drive pathway activation and how best to intervene therapeutically.
References
- 1. Wolfson RL et al.. 2016. Sestrin2 is a leucine sensor for the mTORC1 pathway.. Science 351(6268):43-8 PMID: 26449471
- 2. Yin S et al.. 2024. TREM2 signaling in Parkinson's disease: Regulation of microglial function and α-synuclein pathology.. Int Immunopharmacol 143(Pt 2):113446 PMID: 39490141
- 3. Hasskarl J. 2014. Everolimus.. Recent Results Cancer Res 201:373-92 PMID: 24756805
- 4. Ye M et al.. 2023. FABP5 suppresses colorectal cancer progression via mTOR-mediated autophagy by decreasing FASN expression.. Int J Biol Sci 19(10):3115-3127 PMID: 37416772
- 5. Lv Z et al.. 2023. FOXM1-regulated ZIC2 promotes the malignant phenotype of renal clear cell carcinoma by activating UBE2C/mTOR signaling pathway.. Int J Biol Sci 19(11):3293-3306 PMID: 37496990
- 6. Ren Y et al.. 2026. IMPDH2 facilitates CD4+ T cell activation through AKT/mTOR pathway by upregulating SRPK1 in myasthenia gravis.. Clin Immunol 282:110634 PMID: 41213488
- 7. Kim DH et al.. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.. Cell 110(2):163-75 PMID: 12150925
- 8. Chen Y et al.. 2023. Regulation of CD8(+) T memory and exhaustion by the mTOR signals.. Cell Mol Immunol 20(9):1023-1039 PMID: 37582972
